Cargando…

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia

Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enjeti, Anoop K., D’Crus, Angel, Melville, Kathleen, Verrills, Nicole M., Rowlings, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881728/ https://www.ncbi.nlm.nih.gov/pubmed/26967515 http://dx.doi.org/10.1097/CAD.0000000000000358

Ejemplares similares

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow
por: Berry, Nadine Kaye, et al.
Publicado: (2014)

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
por: Humphries, Sam, et al.
Publicado: (2023)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
por: Staudt, Dilana, et al.
Publicado: (2018)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system
por: Enjeti, Anoop, et al.
Publicado: (2015)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Acute abdomen in a patient with chronic myeloid leukaemia
por: Voppuru, Saiesh Reddy, et al.
Publicado: (2020)

Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia
por: Dun, Matthew D., et al.
Publicado: (2020)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Megaloblastic Erythropoiesis in a Case of Myeloid Leukaemia during Treatment
por: Stone, Frederick H.
Publicado: (1950)

Neurological safety of fingolimod: An updated review
por: Yoshii, Fumihito, et al.
Publicado: (2017)

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
por: Berry, James D., et al.
Publicado: (2017)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

Chronic Myeloid Leukaemia: Report of a Case Surviving Ten Years
por: Hird, Alan J.
Publicado: (1949)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs
por: Hunt, Kooper V., et al.
Publicado: (2022)

TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia
por: Tripon, Florin, et al.
Publicado: (2021)

Erythropoiesis in Murine Myeloid Leukaemia
por: Tanaka, T.
Publicado: (1970)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

A Case of Myeloid Leukæmia
por: Ghosal, J. N.
Publicado: (1931)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly
por: Daly, A.B., et al.
Publicado: (2019)

Human leukaemia: recent tissue culture studies on the nature of myeloid leukaemia.
por: Metcalf, D.
Publicado: (1973)

IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia
por: Kuett, Alexander, et al.
Publicado: (2015)

The power and potential of integrated diagnostics in acute myeloid leukaemia
por: Haferlach, Torsten, et al.
Publicado: (2019)

Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?
por: Valli, Debora, et al.
Publicado: (2020)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?
por: Oel, Dierk, et al.
Publicado: (2021)

Targeting apoptosis in acute myeloid leukaemia
por: Cassier, Philippe A, et al.
Publicado: (2017)

Adhesion Deregulation in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Murine Models of Acute Myeloid Leukaemia
por: Almosailleakh, Marwa, et al.
Publicado: (2019)

Wnt Signalling in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Molecular Mechanisms and Therapies of Myeloid Leukaemia
por: Brown, Elliott, et al.
Publicado: (2022)

Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_02857d0usqmk3vagj38g7pvjjt